2026 GLP-1 Super Bowl Commercials May Be Game Changers for Weight Loss Drugs
New GLP-1 ads, like telehealth provider Ro’s new campaign featuring tennis icon Serena Williams, aim to shift the conversation about weight loss drugs.
This year, the Super Bowl will feature advertising of GLP-1 drugs in new ways.
Telehealth provider Ro is using tennis star Serena Williams to help break down stigma.
Novo’s threat to sue Hims over Wegovy pill faces legal hurdle
Novo Nordisk’s threatened legal action against Hims & Hers for selling a compounded version of the pharma giant’s newly launched Wegovy pill may be far from a slam-dunk win.
Dae Lee, an attorney at Buchanan …
Challenges for a crucial sickle cell treatment and the latest outlook for GLP-1s
This week on “The Readout LOUD”: We discuss financial outlooks from Novo Nordisk and Eli Lilly, a closer look at why manufacturing problems have slowed the rollout of a crucial…
STAT+: Novo Nordisk accuses Hims & Hers of ‘illegal mass compounding’ over a cheaper version of Wegovy pill
Hims & Hers is making available a cheaper, compounded version of the Wegovy weight loss pill sold by Novo Nordisk, prompting the drugmaker to accuse the telehealth platform of “illegal…
Hims & Hers Launches Copy of Wegovy Pill, Prompting Legal Threats
(MedPage Today) — Telehealth company Hims & Hers said Thursday it will launch a cheaper, off-brand version of the weight-loss pill semaglutide (Wegovy), just weeks after drugmaker Novo Nordisk launched its highly anticipated reformulation…
Novo Nordisk vows legal action to protect Wegovy pill
Novo Nordisk said Thursday it would take legal action against a US chain offering a copycat of the new pill version of its Wegovy weight-loss drug.
Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists Use in Elderly People With Obesity-A Meta-Analysis
CONCLUSIONS: GLP-1 RA therapy seems to be safe and effective in older adults with obesity, achieving similar effects on weight loss and glycemic control as in younger individuals.
Efficacy and Safety of Oral GLP-1 RA Orforglipron on Weight and Glycemic Control According to Diabetes Status: A Systematic Review and Meta-Analysis
Excess body weight and poor metabolic control remain major contributors to cardiometabolic disease, highlighting the need for effective therapeutic options. This meta-analysis aimed to evaluate the efficacy and safety of once-daily oral orforglipron in obese adults with and without diabetes. Searches were conducted across four databases through November 2025. Five randomized controlled trials (n = 6140) were included. Orforglipron produced consistent, dose-dependent reductions in body weight,…
A personalized, evidence-based approach to obesity therapy using clinical algorithms: semaglutide or tirzepatide
On June 26, 2025, a meeting of the expert working group was held in Moscow. The discussion focused on the personalized approach of tirzepatide («Tirzetta®») and semaglutide («Velgia Eco®») in patients with excess body weight, obesity, and type 2 diabetes. Following the meeting, the objective was set to develop a consensus-based algorithm for prescribing these drugs to ensure their effective use in Russian clinical practice.
Nutritional status with tirzepatide in obesity: A post hoc analysis of the SURMOUNT-1-4 randomized clinical trials
CONCLUSIONS: TEAEs and treatment discontinuations due to macronutrient malnutrition were uncommon in the SURMOUNT-1-4 trials of tirzepatide for obesity. Lack of routinely collected vitamin and mineral levels during the trials limited assessment of the impact of tirzepatide treatment on micronutrient status. Systematic assessment of nutritional status before and during OMM treatment would enhance future trials.